Latest Content

  • EMA Guidance: Management of Clinical Trials - What it means for Patients?

    EMA Guidance: Management of Clinical Trials - What it means for Patients?

    A lay summary for patients participating in clinical trials

    View Now
  • Putting the Pandemic in Plain Language

    Putting the Pandemic in Plain Language

    The COVID-19 pandemic has brought many negative feelings to the forefront of our everyday lives, including anxiety, fear and social division, but what if we explored the new positive relationships...

    Learn More
  • Navigating new steps in how FDA is managing COVID-19 Products

    Navigating new steps in how FDA is managing COVID-19 Products

    Learn More
  • See Parexel's latest COVID-19 expert content

    View all
  • COVID-19 Impact on Rare Disease Patients and Manufacturers

    COVID-19 Impact on Rare Disease Patients and Manufacturers

    About the Authors Yi Liu, PhD is a Senior Analyst in the Health...

    Learn More
  • ×

    Speak to one of our experts today

    First Name
    Last Name
    Company Name
    Title
    Country
    Tell us how we can help
    We'll be in touch shortly!
    Error - something went wrong!
  • Understanding the COVID-19 regulatory procedures the FDA is using

    Understanding the COVID-19 regulatory procedures the FDA is using

    A diagram that shows various procedural steps when interacting with the FDA through CTAP.

    Learn More
  • How COVID-19 is Accelerating Telemedicine Adoption in Asia Pacific

    How COVID-19 is Accelerating Telemedicine Adoption in Asia Pacific

    About the Authors Gary Cheng is a Vice President of Health Advances and...

    Learn More
  • The Changing Fortunes of Telemedicine in Europe – Past, Present, and Future beyond COVID-19

    The Changing Fortunes of Telemedicine in Europe – Past, Present, and Future beyond COVID-19

    About Health Advances European Practice Health Advances European Practice helps clients navigate through...

    Learn More
  • COVID-19 Vaccine Development - Part 3: Late stage clinical development and field trials

    COVID-19 Vaccine Development - Part 3: Late stage clinical development and field trials

    Following successful completion of Phase 1 healthy subjects’ studies and animal challenge tests as discussed in Part 2, a number of strategies are possible to demonstrate vaccine efficacy. Such...

    Learn More
  • COVID-19 Vaccine Development - Part 2: Non-clinical and Early phase clinical development

    COVID-19 Vaccine Development - Part 2: Non-clinical and Early phase clinical development

    Clearly, the potential for vaccines to enhance rather than protect against infection through the two mechanisms of ADE and ERD discussed in Part 1, highlights the need for studies in animal models...

    Learn More
  • 5 strategies for mitigating the impact of COVID-19 on clinical trials

    5 strategies for mitigating the impact of COVID-19 on clinical trials

    View Now
  • Part Two: The Unique Impact of COVID-19 and Implications for the MSK Industry

    Part Two: The Unique Impact of COVID-19 and Implications for the MSK Industry

    About Health Advances and Our Musculoskeletal Practice Health Advances is a healthcare-focused strategy...

    Learn More
  • The Great Lockdown of 2020: Will the Life Sciences Emerge Unscathed?

    The Great Lockdown of 2020: Will the Life Sciences Emerge Unscathed?

    Learn More
  • Rapid Responders: How Innovative Technologies are Accelerating Development of New Vaccines

    Rapid Responders: How Innovative Technologies are Accelerating Development of New Vaccines

    About the Authors Joseph McInnes, PhD is a Senior Analyst in the Health...

    Learn More
  • Perspective on Enforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency

    Perspective on Enforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency

    In summary FDA is moving quickly to implement emergency use applications (EUAs) policy to provide flexibility to those manufacturers of face masks and respirators to meet the need of medical...

    Learn More
  • Back to the future – Are you prepared to meet unprecedented demand to use old drugs for new purposes?

    Back to the future – Are you prepared to meet unprecedented demand to use old drugs for new purposes?

    There has been significant momentum to begin repurposing existing drugs to find either prophylactic or acute treatments for COVID-19. These activities could result in further strains on...

    Learn More
  • COVID-19 isn’t putting FDA out of the compliance business – Be ready for inspection alternatives

    COVID-19 isn’t putting FDA out of the compliance business – Be ready for inspection alternatives

    Learn More
  • Solutions for sustainable supply chains in a period of global tumult

    Solutions for sustainable supply chains in a period of global tumult

    Learn More
  • Restricted pharmaceutical exports from India: Are you ready to mitigate risk of drug shortages?

    Restricted pharmaceutical exports from India: Are you ready to mitigate risk of drug shortages?

    Learn More
  • CAR-T: How far have we come and where are we going?

    CAR-T: How far have we come and where are we going?

    In this episode, Doug Olson, one of the first CAR-T patients treated on a clinical trial for CLL almost 10 years ago, details his experiences with this therapy in its earliest days....

    Learn More
  • Reflections on Cancer Drug Development Strategies with Newly-Introduced Chinese Regulations

    Reflections on Cancer Drug Development Strategies with Newly-Introduced Chinese Regulations

    The global cancer drug market is set to maintain strong growth over the next decade due to factors such as environmental pollution, population aging, and poor lifestyles that leave...

    Learn More
  • loading
    Loading More...